RETRACTED: Yen et al. Brevilin A Ameliorates Imiquimod-Induced Psoriasis-like Dermatitis and Reduces Th17 Differentiation in Psoriasis Patients. J. Pers. Med. 2022, 12, 1888

Abstract

Full text

The journal retracts the article “Brevilin A Ameliorates Imiquimod-Induced Psoriasis-like Dermatitis and Reduces Th17 Differentiation in Psoriasis Patients” [1], cited above.

Following publication, the authors identified an issue related to the reported mouse strain used in the study and informed the Editorial Office. The original manuscript stated that C57BL/6 mice were used in the in vivo experiments, whereas the correct strain should be BALB/c mice. To address this, the authors submitted supporting documents to verify the experiments were conducted using another mouse strain.

Adhering to our complaints procedure, an investigation was conducted that confirmed that the evidence provided by the authors was not sufficient to rectify the concerns regarding the use of animal subjects in the experiments. As a result, the Editorial Board have agreed to retract this article [1], as per MDPI’s retraction policy (https://www.mdpi.com/ethics#_bookmark30, accessed on 15 October 2024).

This retraction was approved by the Editor-in-Chief of the Journal of Personalized Medicine.

The authors did not agree to this retraction.